<unk>  (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.
Under license from Bukwang, Pharmasset was developing the drug, but its phase III clinical trial (international, multicenter, randomized, double-blind, 96 week QUASH studies) was terminated due to some myopathy cases in patients. It's approval in South Korea was revoked following these findings.
It is a nucleoside analog.
Clevudine
Brivudine
Saquinavir
Stavudine
Entecavir
Nelfinavir
Darunavir
Tipranavir